|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM331273373 |
| 003 |
DE-627 |
| 005 |
20231225213112.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2021 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1002/adma.202103114
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n1104.xml
|
| 035 |
|
|
|a (DE-627)NLM331273373
|
| 035 |
|
|
|a (NLM)34585802
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Du, Yue
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Engineered Bifunctional Proteins for Targeted Cancer Therapy
|b Prospects and Challenges
|
| 264 |
|
1 |
|c 2021
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 17.03.2022
|
| 500 |
|
|
|a Date Revised 17.03.2022
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2021 Wiley-VCH GmbH.
|
| 520 |
|
|
|a Bifunctional proteins (BFPs) are a class of therapeutic agents produced through genetic engineering and protein engineering, and are increasingly used to treat various human diseases, including cancer. These proteins usually have two or more biological functions-specifically recognizing different molecular targets to regulate the related signaling pathways, or mediating effector molecules/cells to kill tumor cells. Unlike conventional small-molecule or single-target drugs, BFPs possess stronger biological activity but lower systemic toxicity. Hence, BFPs are considered to offer many benefits for the treatment of heterogeneous tumors. In this review, the authors briefly describe the unique structural feature of BFP molecules and innovatively divide them into bispecific antibodies, cytokine-based BFPs (immunocytokines), and protein toxin-based BFPs (immunotoxins) according to their mode of action. In addition, the latest advances in the development of BFPs are discussed and the potential limitations or problems in clinical applications are outlined. Taken together, future studies need to be centered on understanding the characteristics of BFPs for optimizing and designing more effective such drugs
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Review
|
| 650 |
|
4 |
|a bifunctional proteins
|
| 650 |
|
4 |
|a classifications
|
| 650 |
|
4 |
|a clinical applications
|
| 650 |
|
4 |
|a effector molecules
|
| 650 |
|
4 |
|a targeted deliveries
|
| 650 |
|
7 |
|a Antibodies, Bispecific
|2 NLM
|
| 650 |
|
7 |
|a Cytokines
|2 NLM
|
| 650 |
|
7 |
|a Immunotoxins
|2 NLM
|
| 700 |
1 |
|
|a Xu, Jian
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Advanced materials (Deerfield Beach, Fla.)
|d 1998
|g 33(2021), 48 vom: 25. Dez., Seite e2103114
|w (DE-627)NLM098206397
|x 1521-4095
|7 nnns
|
| 773 |
1 |
8 |
|g volume:33
|g year:2021
|g number:48
|g day:25
|g month:12
|g pages:e2103114
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1002/adma.202103114
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 33
|j 2021
|e 48
|b 25
|c 12
|h e2103114
|